Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.49 |
| ▸ | RHEB | Q15382 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.32 |
| ▸ | PPIA | P62937 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15732994 | 0.88 | DGAT1 (0.68) | DGAT1RHEBROCK1PTGER1SRD5A2 | |
| SCHEMBL14136848 | 0.84 | DGAT1 (0.59) | DGAT1ROCK1DHODH | |
| SCHEMBL20043820 | 0.79 | RHEB (0.34) | DGAT1RHEBROCK1PTGER1SRD5A2 | |
| SCHEMBL2522702 | 0.78 | MRGPRX4 (0.43) | PTGER1EGFRERBB2 | |
| SCHEMBL15733006 | 0.75 | DGAT1 (0.55) | DGAT1EGFRERBB2 | |
| SCHEMBL14136659 | 0.74 | DGAT1 (0.56) | DGAT1 | |
| SCHEMBL15733018 | 0.74 | DGAT1 (0.62) | DGAT1 | |
| SCHEMBL14136900 | 0.72 | DGAT1 (0.59) | DGAT1 | |
| SCHEMBL15522458 | 0.72 | DGAT1 (0.82) | DGAT1DHODH | |
| SCHEMBL12208122 | 0.72 | MRGPRX4 (0.39) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3492474-B1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3492474-B1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10385066-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385066-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3492474-A1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GlaxoSmithKline LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492474-A1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GlaxoSmithKline LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190135829-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135829-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2017-03-23 | — | — | US | disclosed |
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2017-03-23 | — | — | US | disclosed |
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2017-03-23 | — | — | US | disclosed |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-12 | — | — | US | disclosed |
| WO-2014081994-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885RHEB 2574/4885ROCK1 3849/4885 |
| US-10385066-B2 | Compounds as diacylglycerol acyltransferase inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885RHEB 2261/4885ROCK1 1221/4885 |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885RHEB 2574/4885ROCK1 3849/4885 |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885RHEB 2574/4885ROCK1 3849/4885 |
| US-20190135829-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | DGAT1 1/4885RHEB 2145/4885ROCK1 1566/4885 |
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885RHEB 2261/4885ROCK1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.